The United Russians thought about the Orphans

Gerasimenko: We need to stimulate our pharmaceutical enterpriseser.ru
The problem of orphan (rare) diseases and measures to improve medical care in this area became the main topic of a round table held by the State Duma Committee on Health Protection on Thursday, February 17.

According to news agencies, following the discussion, the first deputy chairman of the State Duma Committee on Health Protection Nikolay Gerasimenko said that specific measures of tax incentives for patrons and manufacturers of medicines intended for the treatment of rare diseases can be taken within one year.

In particular, according to him, "a new version of the law "On the basics of health protection of citizens of the Russian Federation" is being considered. It will determine "what orphan diseases are, who should finance their treatment."

Currently, drug provision for patients with rare diseases should be carried out at the expense of the budgets of the subjects of the Russian Federation in accordance with the decree of the Government of the Russian Federation and with target programs adopted at the regional level. However, as Gerasimenko explained, the current norms do not establish "direct obligations of the regions to do this." "Moreover, it turned out that half of the subjects of the Federation do not finance this direction at all." In this regard, the participants of the round table recommended to regional executive authorities "that there be a more rigid form of decision-making - at the level of by-laws," the United Russia deputy stressed. In this regard, he stated that "there is still not enough money at the federal level for everyone." Therefore, it is necessary to "think about what can be included in the program of state guarantees of state medical care."

In addition, Gerasimenko spoke in favor of "excluding donations from sponsors, patrons for the treatment of orphan diseases from the taxable amount, so that they participate more actively in this." He also drew attention to the fact that "we practically do not produce orphan drugs."

Considering this, "it is necessary to stimulate our pharmaceutical enterprises with tax benefits and customs duties on imported substances," the deputy believes. In his opinion, legislative decisions on the last two aspects "can be taken within a year."

Portal "Eternal youth" http://vechnayamolodost.ru21.02.2011